Eisai will present five-year lecanemab and real-world Alzheimer's data at CTAD 2026. Explore the key efficacy and safety questions.
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.